I agree that BOTA should be leaner and meaner. Personally, I...

I agree that BOTA should be leaner and meaner.

Personally, I would just pursue opportunities to progress the IP that we have and start to give back to shareholders rather than invest in new later stage opportunities- if DS wants ROW and give us 4% I would be fine with that- as has been said $80 million in other late stage opportunities wont go far. That said if they want to take over Pharmaxis (PXS) for $50 million (and have access to their $34 million cash at bank) and become a real powerhouse in respiratory health they have my blessing.

I want to see royalties from Relenza and lani (say $10 million+ per annum) pay for a lean operating costs at BOTA and most of the remainder come back to shareholders as dividends (or they can do a stock buy back if that is more tax effective for us aussie holders).

no R and D spend, no marketing costs, scant personnel costs, scant PPE costs, no risk